Vetsys Pharmaceutical
Vetsys Pharmaceutical
The global coccidiostat premixes market is currently witnessing a significant transformation. As the demand for poultry and livestock protein continues to rise globally, the prevention of coccidiosis—a parasitic disease caused by Eimeria species—has become a top priority for commercial farmers. Coccidiostat premixes remain the primary defense mechanism, integrated directly into animal feed to ensure continuous protection during critical growth phases.
Modern industrial trends are shifting from pure chemical coccidiostats toward ionophores and vaccination-rotation programs. Manufacturers are now focusing on formulations that minimize drug resistance. The development of high-bioavailability premixes, such as those produced by Zhengzhou Vetsys, ensures that even lower dosages achieve maximum therapeutic efficacy.
B2B procurement for large-scale livestock operations now emphasizes GMP (Good Manufacturing Practice) compliance and full traceability. Global buyers from Southeast Asia, Africa, and South America are increasingly seeking reliable Chinese manufacturers who can offer a balance between cost-effectiveness and strict pharmaceutical standards.
The following list represents the industry's most influential manufacturers, selected based on their R&D capabilities, market share, and commitment to GMP standards.
A global leader known for ionophore-based coccidiostats, setting the standard for broiler health management.
Specializes in both fermentation-derived and synthetic coccidiostats with a strong European presence.
A leading high-tech enterprise with 30 million RMB registered capital and an independent research institute with 5 specialized labs.
The largest global animal health company, offering a wide array of feed additives and vaccines.
Highly regarded for their medicated feed additives and specialty nutritional products for livestock.
Focuses on comprehensive health solutions including advanced parasitology products.
Renowned for its commitment to poultry health and innovative vaccination programs alongside premixes.
Known for high-quality research and a strong portfolio in swine and avian health management.
Offers localized solutions across various continents, focusing on veterinary pharmaceutical excellence.
Leading the way in natural feed additives and mycotoxin management, often used in conjunction with coccidiostats.
Established in 2005, Zhengzhou Vetsys Pharmaceutical Co., Ltd. (Vetsys) is a leading manufacturer in the animal pharmaceutical industry. With a registered capital of 30 million RMB, Vetsys has built a reputation for excellence and reliability.
Our facility includes specialized workshops for producing a wide range of products, including powders & premixes, injections, oral solutions, tablets, granules, and herbal drug extracts. We operate in strict compliance with Good Manufacturing Practices (GMP), ensuring that every batch of Coccidiostat Premix meets the highest global quality standards.
By 2015, Vetsys achieved annual sales of over USD 20 million in the domestic market, solidifying our position as a top-tier producer in China.
Vetsys distinguishes itself from competitors by placing a strong emphasis on technological development and continuous innovation. We have established an independent research institute equipped with five specialized laboratories and a team of world-class scientists. This enables us to quickly adapt to market demands and produce cutting-edge solutions for animal health.
Our commitment to research ensures that Vetsys remains at the forefront of the industry, continuously enhancing our product offerings and contributing to advancements in animal healthcare. From improving the bioavailability of active ingredients like Amoxicillin and Tiamulin to developing sustainable, eco-friendly premixes, our R&D team is the engine of our growth.
Quality is the cornerstone of our operations. Vetsys has developed a comprehensive quality management system to oversee every aspect of production. We adhere to rigorous GMP standards, ensuring that all products undergo extensive quality control checks before reaching the market. This focus maintains trust among our global partners.
We continue to invest in green technologies and environmentally friendly practices. Our products are not only designed for efficacy but also to promote the overall well-being of both animals and the environment. Minimizing our carbon footprint is part of our long-term vision for a healthier planet.
Vetsys is actively exploring international expansion, aiming to bring high-quality, innovative animal health solutions to global markets. Our future strategy includes partnerships, research collaborations, and expanding our manufacturing capabilities to meet the increasing demand for safe and effective animal drugs worldwide.
At Vetsys, we are driven by our mission to improve animal health through continuous innovation, world-class quality, and sustainable practices. We remain committed to creating value for our customers, employees, and society as we continue to shape the future of animal healthcare.
